Sanofi [NASDAQ: SNY] traded at a high on 11/16/22, posting a 0.71 gain after which it closed the day’ session at $43.86. The company report on November 14, 2022 that Sanofi: Information concerning the total number of voting rights and shares – October 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).
Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 46, avenue de la Grande Armée – 75017 Paris – FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844.
The results of the trading session contributed to over 4520729 shares changing hands. Over the past one week, the price volatility of Sanofi stands at 1.87% while the volatility over the past one month is 1.59%.
The market cap for SNY stock reached $113.09 billion, with 2.50 billion shares outstanding and 2.26 billion shares in the current float. Compared to the average trading volume of 3.14M shares, SNY reached a trading volume of 4520729 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sanofi [SNY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNY shares is $59.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNY stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Sanofi shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 12, 2022. The new note on the price target was released on August 09, 2022, representing the official price target for Sanofi stock.
The Average True Range (ATR) for Sanofi is set at 0.89, with the Price to Sales ratio for SNY stock in the period of the last 12 months amounting to 2.50. The Price to Book ratio for the last quarter was 1.55, with the Price to Cash per share for the same quarter was set at 2.73.
How has SNY stock performed recently?
Sanofi [SNY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.20. With this latest performance, SNY shares gained by 9.51% in over the last four-week period, additionally sinking by -15.83% over the last 6 months – not to mention a drop of -13.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNY stock in for the last two-week period is set at 62.50, with the RSI for the last a single of trading hit 63.47, and the three-weeks RSI is set at 59.58 for Sanofi [SNY]. The present Moving Average for the last 50 days of trading for this stock 40.73, while it was recorded at 43.55 for the last single week of trading, and 48.17 for the last 200 days.
Sanofi [SNY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sanofi [SNY] shares currently have an operating margin of +22.95 and a Gross Margin at +63.07. Sanofi’s Net Margin is presently recorded at +16.48.
Return on Total Capital for SNY is now 9.72, given the latest momentum, and Return on Invested Capital for the company is 7.26. Return on Equity for this stock inclined to 9.45, with Return on Assets sitting at 5.30. When it comes to the capital structure of this company, Sanofi [SNY] has a Total Debt to Total Equity ratio set at 32.63. Additionally, SNY Total Debt to Total Capital is recorded at 24.61, with Total Debt to Total Assets ending up at 18.64. Long-Term Debt to Equity for the company is recorded at 27.61, with the Long-Term Debt to Total Capital now at 20.82.
Reflecting on the efficiency of the workforce at the company, Sanofi [SNY] managed to generate an average of $65,202 per employee. Receivables Turnover for the company is 3.83 with a Total Asset Turnover recorded at a value of 0.32.Sanofi’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.30.
Earnings analysis for Sanofi [SNY]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sanofi go to 12.30%.
Insider trade positions for Sanofi [SNY]
There are presently around $11,294 million, or 10.50% of SNY stock, in the hands of institutional investors. The top three institutional holders of SNY stocks are: DODGE & COX with ownership of 75,650,666, which is approximately -1.749% of the company’s market cap and around 16.40% of the total institutional ownership; FMR LLC, holding 18,203,971 shares of the stock with an approximate value of $798.43 million in SNY stocks shares; and BOSTON PARTNERS, currently with $777.34 million in SNY stock with ownership of nearly 48.926% of the company’s market capitalization.
Positions in Sanofi stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 262 institutional holders increased their position in Sanofi [NASDAQ:SNY] by around 28,015,321 shares. Additionally, 332 investors decreased positions by around 31,732,130 shares, while 123 investors held positions by with 197,752,635 shares. The mentioned changes placed institutional holdings at 257,500,086 shares, according to the latest SEC report filing. SNY stock had 67 new institutional investments in for a total of 4,964,161 shares, while 123 institutional investors sold positions of 5,631,465 shares during the same period.